1 Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
2 Department of Pediatrics and.
Am J Respir Crit Care Med. 2018 Mar 1;197(5):589-594. doi: 10.1164/rccm.201705-1021OC.
Experimental evidence suggests that CDHR3 (cadherin-related family member 3) is a receptor for rhinovirus (RV)-C, and a missense variant in this gene (rs6967330) is associated with childhood asthma with severe exacerbations.
To determine whether rs6967330 influences RV-C infections and illnesses in early childhood.
We studied associations between rs6967330 and respiratory infections and illnesses in the COPSAC (Copenhagen Prospective Studies on Asthma in Childhood 2010) and COAST (Childhood Origins of Asthma Birth Cohort Study) birth cohorts, where respiratory infections were monitored prospectively for the first 3 years of life. Nasal samples were collected during acute infections in both cohorts and during asymptomatic periods in COAST and analyzed for RV-A, RV-B, and RV-C, and other common respiratory viruses.
The CDHR3 asthma risk allele (rs6967330-A) was associated with increased risk of respiratory tract illnesses (incidence risk ratio [IRR] = 1.14 [95% confidence interval, 1.05-1.23]; P = 0.003). In particular, this variant was associated with risk of respiratory episodes with detection of RV-C in COPSAC (IRR = 1.89 [1.14-3.05]; P = 0.01) and in COAST (IRR = 1.37 [1.02-1.82]; P = 0.03) children, and in a combined meta-analysis (IRR = 1.51 [1.13-2.02]; P = 0.006). In contrast, the variant was not associated with illnesses related to other viruses (IRR = 1.07 [0.92-1.25]; P = 0.37). Consistent with these observations, the CDHR3 variant was associated with increased detection of RV-C, but not of other viruses during scheduled visits at specific ages.
The CDHR3 asthma risk allele is associated specifically with RV-C illnesses in two birth cohorts. This clinical evidence supports earlier molecular evidence indicating that CDHR3 functions as an RV-C receptor, and raises the possibility of preventing RV-C infections by targeting CDHR3.
实验证据表明 CDHR3(钙粘蛋白相关家族成员 3)是鼻病毒(RV-C)的受体,该基因的一个错义变异(rs6967330)与严重加重的儿童哮喘有关。
确定 rs6967330 是否会影响儿童早期的 RV-C 感染和疾病。
我们研究了 COPSAC(哥本哈根儿童哮喘前瞻性研究 2010 年)和 COAST(儿童哮喘起源出生队列研究)两个出生队列中 rs6967330 与呼吸道感染和疾病之间的关联,在这两个队列中,前瞻性地监测了生命的前 3 年的呼吸道感染。在 COAST 队列中,在急性感染期间和无症状期间收集了鼻腔样本,并对其进行了 RV-A、RV-B 和 RV-C 以及其他常见呼吸道病毒的分析。
CDHR3 哮喘风险等位基因(rs6967330-A)与呼吸道疾病风险增加相关(发病率风险比 [IRR] = 1.14 [95%置信区间,1.05-1.23];P = 0.003)。特别是,该变异与 COPSAC 中 RV-C 检测到的呼吸道发作风险相关(IRR = 1.89 [1.14-3.05];P = 0.01)和 COAST 儿童(IRR = 1.37 [1.02-1.82];P = 0.03),以及合并的荟萃分析(IRR = 1.51 [1.13-2.02];P = 0.006)。相比之下,该变异与其他病毒相关的疾病无关(IRR = 1.07 [0.92-1.25];P = 0.37)。与这些观察结果一致的是,在特定年龄的计划访问期间,该变异与 RV-C 的检测增加有关,但与其他病毒无关。
CDHR3 哮喘风险等位基因与两个出生队列中特定的 RV-C 疾病有关。这一临床证据支持了早期的分子证据,表明 CDHR3 作为 RV-C 受体发挥作用,并提出了通过靶向 CDHR3 来预防 RV-C 感染的可能性。